Medical device and MedTech insights, news, tips and more

Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius High Frequency Nerve Block System

July 5, 2021

Neuros Medical Logo

Neuros Medical, Inc., announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel High-Frequency Nerve Block system as an aid in the management of chronic intractable pain of the lower limb of adult amputees.

The FDA Breakthrough Device Program is intended to help patients and health care providers receive timely access to medical devices that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.

In the United States alone, there are nearly two million lower limb amputees, with 160,000 new amputations occurring annually.  Chronic post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.  Chronic post-amputation pain is estimated to afflict approximately 30% to 80% of patients who undergo a major limb amputation.

Neuros anticipates completion of enrollment in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study by the Fall of 2021. QUEST is a 180-subject, randomized, double blinded, active sham controlled clinical trial that is being conducted under an Investigational Device Exemption (IDE).  QUEST is designed to assess the safety & effectiveness of the Company’s Altius® High-Frequency Nerve Block system to treat intractable chronic post-amputation pain.

“The Altius System – as a designated Breakthrough Device – is the result of outstanding multi-disciplinary teamwork, and we look forward to completion of QUEST enrollment this Fall as another key milestone in our effort to develop this important therapy option for patients who suffer from chronic post-amputation pain,” said William Patterson PhD, Chief Technology Officer.

See Full Press Release at the Source: Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System

Press Release by: Neuros Medical

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

October 12, 2023
Brainomix and Nanoflex Robotics to Collaborate on an AI-Assisted Robotic System for Remote Stroke Intervention
Learn More
October 10, 2023
FDA clears Intelivation Technologies new Hammerdesis™ Interphalangeal Fusion System
Learn More
October 9, 2023
FDA Awards HistoSonics Clearance of its First-of-a-Kind Edison® Histotripsy System
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.